Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12614000869673
Ethics application status
Approved
Date submitted
17/07/2014
Date registered
13/08/2014
Date last updated
13/08/2014
Type of registration
Retrospectively registered
Titles & IDs
Public title
Effect of flouxetine versus citalopram on sexual dysfunction, serum oxytocin and prolactin levels in women
Query!
Scientific title
Sexual dysfunction, serum oxytocin and prolactin level in women with diagnosis of depression treated with flouxetine or citalopram
Query!
Secondary ID [1]
285004
0
nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Sexual dysfunction
292511
0
Query!
Depression
292645
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
292818
292818
0
0
Query!
Other reproductive health and childbirth disorders
Query!
Mental Health
292956
292956
0
0
Query!
Depression
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Administration arm1:oral tablet of flouxetine 20 mg/day for 4 weeks or arm 2: oral tablet of citalopram 20 mg/day for 4 weeks both for treatment of major depressive disorder in women. Adherence monitoring will be done by counting tablet return by patients.
Query!
Intervention code [1]
289837
0
Treatment: Drugs
Query!
Comparator / control treatment
Fluoxetine group
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
292677
0
Using Female Sexual Function Index(FSFI) questionairre for assesment of sexual dysfunction
Query!
Assessment method [1]
292677
0
Query!
Timepoint [1]
292677
0
After 4 weeks of treatment either with flouxetine or citalopram
Query!
Secondary outcome [1]
309492
0
assesment of oxytocin in serum of studied patients
Query!
Assessment method [1]
309492
0
Query!
Timepoint [1]
309492
0
After 4 weeks of treatment with either flouxetine or citalopram
Query!
Secondary outcome [2]
309728
0
Assessment of prolactin in serum of studied patient
Query!
Assessment method [2]
309728
0
Query!
Timepoint [2]
309728
0
After 4 weeks of treatment with either fluoxetine or citalopram
Query!
Eligibility
Key inclusion criteria
All women need to be experiencing symptoms of sexual dysfunction with diagnosis of depression between 18-45 years old in the psychosomatic clinic of Taleghani hospital(Tehran, Iran) with informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
patients with renal failure or hepatic failure, pregnat or breast feeding women
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
21/02/2013
Query!
Actual
21/02/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
8/01/2014
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
6223
0
Iran, Islamic Republic Of
Query!
State/province [1]
6223
0
Query!
Funding & Sponsors
Funding source category [1]
289619
0
University
Query!
Name [1]
289619
0
Shahid Beheshti University of Medical Sciences
Query!
Address [1]
289619
0
Department of clinical pharmacy, school of pharmacy, valiasr street, nyayesh junction, Tehran, Iran, 1991953381
Query!
Country [1]
289619
0
Iran, Islamic Republic Of
Query!
Primary sponsor type
Individual
Query!
Name
Mohammad Abbasinazari
Query!
Address
Department of clinical pharmacy, school of pharmacy,Shahid Beheshti University of Medical Sciences, valiasr street, nyayesh junction, Tehran, Iran, 1991953381
Query!
Country
Iran, Islamic Republic Of
Query!
Secondary sponsor category [1]
288306
0
University
Query!
Name [1]
288306
0
Deputy of research of Shahid Beheshti university of medical sciences
Query!
Address [1]
288306
0
Deputy of research, School of pharmacy, valiasr street, nyayesh junction, Tehran, Iran, 1991953381
Query!
Country [1]
288306
0
Iran, Islamic Republic Of
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
291361
0
Shahid Beheshti University of Medical Sciences ethical committee
Query!
Ethics committee address [1]
291361
0
Ethical comittee center, school of pharmacy, valiasr street, nyayesh jnction, Tehran, Iran, 1991953381
Query!
Ethics committee country [1]
291361
0
Iran, Islamic Republic Of
Query!
Date submitted for ethics approval [1]
291361
0
27/06/2012
Query!
Approval date [1]
291361
0
27/06/2012
Query!
Ethics approval number [1]
291361
0
Query!
Summary
Brief summary
Sexual dysfunction is an important adverse drug reactions of selective serotonin reuptake inhibitor(SSRIs) drugs. In some limited animal studies sexual dysfunction has been related to changes in oxytocin and prolactin levels due to usage of SSRIs. Flouxetine can cause more suppression in oxytocin than citalopram and less suppression in prolactin than citalopram. It has been postulated that decrease in oxytocin and increase in prolactin is responsible for more sexual abnormality adverse effects by fluoxetine versus citalopram. In this study we have selected some depressed women who need to starting an SSRIs. We randomized depressed women to give either fluoxetine 20 mg/day or citalopram 20 mg/day. After 4 weeks we have determined sexual dysfunction and oxytocin and prolactin levels in both groups. Finally severity of sexual dysfunction and oxytocin and prolactin will be compare in two groups.
Query!
Trial website
Query!
Trial related presentations / publications
There is not any citation. Now we are writing a manuscript for publication.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
49998
0
A/Prof Mohammad Abbasinazari
Query!
Address
49998
0
Department of clinical pharmacy,School of pharmacy, Shahid Beheshti University of Medical Sciences,Valiasr street, nyayesh junction, Tehran, Iran 1991953381
Query!
Country
49998
0
Iran, Islamic Republic Of
Query!
Phone
49998
0
+982188873704
Query!
Fax
49998
0
Query!
Email
49998
0
[email protected]
Query!
Contact person for public queries
Name
49999
0
Mohammad Abbasinazari
Query!
Address
49999
0
Department of clinical pharmacy,School of pharmacy, Shahid Beheshti University of Medical Sciences,Valiasr street, nyayesh junction, Tehran, Iran 1991953381
Query!
Country
49999
0
Iran, Islamic Republic Of
Query!
Phone
49999
0
+982188873704
Query!
Fax
49999
0
Query!
Email
49999
0
[email protected]
Query!
Contact person for scientific queries
Name
50000
0
Mohammad Abbasinazari
Query!
Address
50000
0
Department of clinical pharmacy,School of pharmacy, Shahid Beheshti University of Medical Sciences,Valiasr street, nyayesh junction, Tehran, Iran 1991953381
Query!
Country
50000
0
Iran, Islamic Republic Of
Query!
Phone
50000
0
+982188873704
Query!
Fax
50000
0
Query!
Email
50000
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Plasma oxytocin level and sexual dysfunction in depressed women treated by either fluoxetine or citalopram: A pilot clinical trial.
2018
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF